Spectrascience Financial Statements From 2010 to 2025
Spectrascience New financial statements provide useful quarterly and yearly information to potential Spectrascience New investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Spectrascience New financial statements helps investors assess Spectrascience New's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Spectrascience New's valuation are summarized below:Spectrascience New does not presently have any fundamental trend indicators for analysis.
Check out the analysis of Spectrascience New Correlation against competitors. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.
Check Spectrascience New financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spectrascience New's main balance sheet or income statement drivers, such as , as well as many indicators such as . Spectrascience financial statements analysis is a perfect complement when working with Spectrascience New Valuation or Volatility modules.
Spectrascience |
Spectrascience New Company Return On Asset Analysis
Spectrascience New's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Spectrascience New Return On Asset | -0.92 |
Most of Spectrascience New's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spectrascience New is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Spectrascience New has a Return On Asset of -0.9247. This is 89.43% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Spectrascience New Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spectrascience New competition to find correlations between indicators driving Spectrascience New's intrinsic value. More Info.Spectrascience New is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Spectrascience New Financial Statements
Spectrascience New stakeholders use historical fundamental indicators, such as Spectrascience New's revenue or net income, to determine how well the company is positioned to perform in the future. Although Spectrascience New investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spectrascience New's assets and liabilities are reflected in the revenues and expenses on Spectrascience New's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spectrascience New. Please read more on our technical analysis and fundamental analysis pages.
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California. Spectrascience operates under Medical Appliances Equipment classification in the United States and is traded on OTC Exchange. It employs 5 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spectrascience New is a strong investment it is important to analyze Spectrascience New's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectrascience New's future performance. For an informed investment choice regarding Spectrascience Stock, refer to the following important reports:Check out the analysis of Spectrascience New Correlation against competitors. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.